E.P. Hamilton

1.6k total citations
29 papers, 317 citations indexed

About

E.P. Hamilton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, E.P. Hamilton has authored 29 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in E.P. Hamilton's work include HER2/EGFR in Cancer Research (14 papers), Advanced Breast Cancer Therapies (13 papers) and Cancer Treatment and Pharmacology (5 papers). E.P. Hamilton is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Advanced Breast Cancer Therapies (13 papers) and Cancer Treatment and Pharmacology (5 papers). E.P. Hamilton collaborates with scholars based in United States, United Kingdom and Italy. E.P. Hamilton's co-authors include Anja von Heydebreck, H-T. Arkenau, István Takács, L. Dirix, Kevin M. Chin, Guy Jérusalem, Petros Nikolinakos, Sunil Verma, Giuseppe Curigliano and Emarjola Bako and has published in prestigious journals such as Cancer Research, Annals of Oncology and European Journal of Cancer.

In The Last Decade

E.P. Hamilton

26 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E.P. Hamilton United States	8	272	124	91	51	46	29	317
Carmine Valenza Italy	10	185 0.7×	86 0.7×	65 0.7×	35 0.7×	87 1.9×	47	311
Peter Schmid United States	5	227 0.8×	113 0.9×	65 0.7×	15 0.3×	48 1.0×	11	268
Wangjuh Chen United States	4	175 0.6×	119 1.0×	27 0.3×	22 0.4×	84 1.8×	4	252
Mahesh Shivhare United Kingdom	8	178 0.7×	80 0.6×	53 0.6×	33 0.6×	48 1.0×	14	256
Rin Ogiya Japan	8	228 0.8×	129 1.0×	23 0.3×	74 1.5×	66 1.4×	16	305
Yujun Park South Korea	11	226 0.8×	114 0.9×	19 0.2×	86 1.7×	53 1.2×	19	332
Luca Boscolo Bielo Italy	10	132 0.5×	63 0.5×	40 0.4×	15 0.3×	79 1.7×	27	211
MF Press United States	9	233 0.9×	54 0.4×	117 1.3×	11 0.2×	74 1.6×	30	279
Maria Cristina Pirosa Switzerland	10	119 0.4×	59 0.5×	74 0.8×	46 0.9×	41 0.9×	28	305
Emine Bozkurtlar Türkiye	7	195 0.7×	196 1.6×	36 0.4×	27 0.5×	51 1.1×	27	297

Countries citing papers authored by E.P. Hamilton

Since Specialization

Citations

This map shows the geographic impact of E.P. Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.P. Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.P. Hamilton more than expected).

Fields of papers citing papers by E.P. Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.P. Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.P. Hamilton. The network helps show where E.P. Hamilton may publish in the future.

Co-authorship network of co-authors of E.P. Hamilton

This figure shows the co-authorship network connecting the top 25 collaborators of E.P. Hamilton. A scholar is included among the top collaborators of E.P. Hamilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.P. Hamilton. E.P. Hamilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laurentiis, Michelino De, Xin Hu, Marina Elena Cazzaniga, et al.. (2025). 489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial. Annals of Oncology. 36. S380–S381. 1 indexed citations

Yap, Timothy A., Minal Barve, E.P. Hamilton, et al.. (2025). 924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors. Annals of Oncology. 36. S566–S567. 1 indexed citations

Saura, Cristina, Javier Cortés, Shanu Modi, et al.. (2025). Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Annals of Oncology. 37(3). 353–363.

Tarantino, Paolo, H. S. Rugo, Joyce O’Shaughnessy, et al.. (2025). Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis. ESMO Open. 10(6). 105304–105304.

O’Shaughnessy, Joyce, P. Schmid, Zhimin Shao, et al.. (2024). 436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer. Annals of Oncology. 35. S403–S403. 1 indexed citations

Hamilton, E.P., Nicholas P. McAndrew, Melinda L. Telli, et al.. (2024). 218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results. ESMO Open. 9. 103240–103240. 7 indexed citations

Patel, Manish, E.P. Hamilton, Sarina A. Piha‐Paul, et al.. (2024). 610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6. Annals of Oncology. 35. S488–S489. 7 indexed citations

Hamilton, E.P., Rachel M. Layman, Michael Danso, et al.. (2024). 637P AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer. Annals of Oncology. 35. S505–S506.

Hurvitz, Sara A., Anne F. Schott, X. Cynthia, et al.. (2023). 205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 8(1). 101394–101394. 6 indexed citations

10.

Cortés, Javier, Hitoshi Iwata, E.P. Hamilton, et al.. (2022). 236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1). Annals of Oncology. 33. S645–S646. 1 indexed citations

11.

Jhaveri, Komal, Hyo S. Han, Efrat Dotan, et al.. (2022). 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Annals of Oncology. 33. S749–S750. 44 indexed citations

12.

Hamilton, E.P., Charles L. Shapiro, Valentina Boni, et al.. (2022). 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer. Annals of Oncology. 33. S196–S196. 31 indexed citations

13.

Vergote, I., E.P. Hamilton, Giorgio Valabrega, et al.. (2022). VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Annals of Oncology. 33(4). 448–450. 8 indexed citations

14.

O’Shaughnessy, Joyce, Priya Rastogi, Nadia Harbeck, et al.. (2021). VP8-2021: Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE. Annals of Oncology. 32(12). 1646–1649. 5 indexed citations

15.

O’Shaughnessy, Joyce, Adam Brufsky, Hope S. Rugo, et al.. (2021). 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC). Annals of Oncology. 32. S473–S474. 2 indexed citations

16.

Johnston, Stephen, Nadia Harbeck, Roberto Hegg, et al.. (2020). LBA5_PR Abemaciclib in high risk early breast cancer. Annals of Oncology. 31. S1143–S1144. 2 indexed citations

17.

Hamilton, E.P., Rebecca C. Arend, Christina Chu, et al.. (2020). 839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer. Annals of Oncology. 31. S629–S630. 1 indexed citations

18.

Beeram, M., E.P. Hamilton, Mariela Blum Murphy, et al.. (2017). Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. Annals of Oncology. 28. v82–v82. 4 indexed citations

19.

Hamilton, E.P., P. Kelly Marcom, Novera Herbert Spector, et al.. (2013). Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer. Cancer Research. 73(24_Supplement). S4–3. 3 indexed citations

20.

Jenkins, Valerie, Lesley Fallowfield, Trudi Edginton, Heather Payne, & E.P. Hamilton. (2005). Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Current Medical Research and Opinion. 21(9). 1329–1335. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact